S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:KURA

Kura Oncology Stock Forecast, Price & News

$20.25
-0.10 (-0.49 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.95
$20.43
50-Day Range
$15.42
$20.96
52-Week Range
$15.12
$43.00
Volume353,120 shs
Average Volume671,336 shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.83
30 days | 90 days | 365 days | Advanced Chart
Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.


Kura Oncology logo

About Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

973rd out of 1,352 stocks

Pharmaceutical Preparations Industry

478th out of 666 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Kura Oncology
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Thursday, August, 5th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.
View Kura Oncology's earnings history
.

How has Kura Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 109.8% and is now trading at $20.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KURA?

8 equities research analysts have issued 1 year price objectives for Kura Oncology's shares. Their forecasts range from $33.00 to $56.00. On average, they expect Kura Oncology's share price to reach $42.44 in the next year. This suggests a possible upside of 109.6% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Troy E. Wilson, Chairman, President & Chief Executive Officer
  • Kathleen Ford, Chief Operating Officer
  • Marc Edward Grasso, Chief Financial & Business Officer
  • Stephen Dale, Chief Medical Officer
  • Mollie Leoni, Vice President-Clinical Development

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.77%), BlackRock Inc. (7.49%), Avoro Capital Advisors LLC (6.24%), Vanguard Group Inc. (4.95%), State Street Corp (4.91%) and Invesco Ltd. (2.30%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology
.

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., FMR LLC, Goldman Sachs Group Inc., BlackRock Inc., Acuta Capital Partners LLC, Invesco Ltd., Bank of New York Mellon Corp, and Wells Fargo & Company MN. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology
or view top insider-selling stocks.

Which institutional investors are buying Kura Oncology stock?

KURA stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, State Street Corp, Renaissance Technologies LLC, Woodline Partners LP, Franklin Resources Inc., Morgan Stanley, Morgan Stanley, and Sphera Funds Management LTD..
View insider buying and selling activity for Kura Oncology
or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $20.25.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $1.34 billion. The company earns $-89,630,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 89 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 500-8800 or via email at [email protected].


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.